AR070218A1 - COMPUESTOS TRICíCLICOS, SUS PROFÁRMACOS, UNA COMPOSICIoN FARMACÉUTICA QUE LOS COMPRENDE Y SU USO EN LA PRODUCCIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR EL RECEPTOR CRF. - Google Patents
COMPUESTOS TRICíCLICOS, SUS PROFÁRMACOS, UNA COMPOSICIoN FARMACÉUTICA QUE LOS COMPRENDE Y SU USO EN LA PRODUCCIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR EL RECEPTOR CRF.Info
- Publication number
- AR070218A1 AR070218A1 ARP090100180A ARP090100180A AR070218A1 AR 070218 A1 AR070218 A1 AR 070218A1 AR P090100180 A ARP090100180 A AR P090100180A AR P090100180 A ARP090100180 A AR P090100180A AR 070218 A1 AR070218 A1 AR 070218A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- crf
- nitrogen
- propharms
- mediationed
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 4
- 229910052757 nitrogen Inorganic materials 0.000 abstract 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 3
- 125000002252 acyl group Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 125000001183 hydrocarbyl group Chemical group 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000006545 (C1-C9) alkyl group Chemical group 0.000 abstract 1
- QACVMDXTCPLKOG-UHFFFAOYSA-N 2,4,7-trichloro-9-(4-methylphenyl)-7,8-dihydro-6h-purino[7,8-a]pyrimidine Chemical compound C1=CC(C)=CC=C1N1C2=NC3=NC(Cl)=NC(Cl)=C3N2CC(Cl)C1 QACVMDXTCPLKOG-UHFFFAOYSA-N 0.000 abstract 1
- 125000005330 8 membered heterocyclic group Chemical group 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 108010056643 Corticotropin-Releasing Hormone Receptors Proteins 0.000 abstract 1
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 150000002829 nitrogen Chemical class 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 1
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Una de sus sales o uno de sus profármacos, que tienen actividad antagonista del receptor CRF y su uso en medicamentos y en composiciones farmacéuticas. Reivindicacion 1 Un compuesto caracterizado por la formula (1'): en donde X es un nitrogeno o CRx (en donde Rx es un hidrogeno o un alquilo C1-9, con la condicion de que, cuando X forma un enlace doble, Rx esté ausente); R1 es (1) un grupo hidrocarbonado opcionalmente sustituido, (2) un acilo, (3) un grupo heterocíclico opcionalmente sustituido, (4) un amino opcionalmente sustituido, (5) nitro, (6) un hidroxi opcionalmente sustituido, (7) un mercapto opcionalmente sustituido, (8) ciano, o (9) halogeno; R2 es (1) un grupo hidrocarbonado opcionalmente sustituido, (2) un acilo, (3) un grupo heterocíclico opcionalmente sustituido, o (4) un amino opcionalmente sustituido con la condicion de que se excluyan metilo, etilo, propilo y metoximetilo; el anillo A es un anillo heterocíclico de 5 a 8 miembros opcionalmente sustituido; y Y1, Y2, e Y3 son cada uno un carbono o un nitrogeno opcionalmente sustituido; excluyendo (i) un compuesto en donde Y1 e Y3 son cada uno un nitrogeno, R1 es amino y es un alquilo opcionalmente sustituido, (ii) 2,4,7-tricloro-9-(4-metilfenil)-6,7,8,9-tetrahidropirimido[2,1-f]purina, (iii) N-acetil-N-(8-acetil-7,8-dihidro-6H-imidazo [2,1-f]purin-4-il)acetamida, y (iv) un compuesto en donde R1 y R2 son cada uno, de modo simultáneo el grupo de formulas (2) o una de sus sales.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US655408P | 2008-01-22 | 2008-01-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR070218A1 true AR070218A1 (es) | 2010-03-25 |
Family
ID=40637104
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090100180A AR070218A1 (es) | 2008-01-22 | 2009-01-21 | COMPUESTOS TRICíCLICOS, SUS PROFÁRMACOS, UNA COMPOSICIoN FARMACÉUTICA QUE LOS COMPRENDE Y SU USO EN LA PRODUCCIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR EL RECEPTOR CRF. |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US8901141B2 (es) |
| EP (1) | EP2240485B1 (es) |
| JP (1) | JP5431341B2 (es) |
| KR (1) | KR20100130596A (es) |
| CN (1) | CN101981031A (es) |
| AR (1) | AR070218A1 (es) |
| AU (1) | AU2009206936A1 (es) |
| BR (1) | BRPI0907230A2 (es) |
| CA (1) | CA2712347A1 (es) |
| CL (1) | CL2009000116A1 (es) |
| CO (1) | CO6230982A2 (es) |
| CR (1) | CR11636A (es) |
| DO (1) | DOP2010000226A (es) |
| EA (1) | EA201070876A1 (es) |
| EC (1) | ECSP10010414A (es) |
| GE (1) | GEP20125637B (es) |
| IL (1) | IL207074A0 (es) |
| MA (1) | MA32438B1 (es) |
| MX (1) | MX2010008039A (es) |
| NZ (1) | NZ587215A (es) |
| PE (1) | PE20091439A1 (es) |
| SG (1) | SG189803A1 (es) |
| TW (1) | TW200936591A (es) |
| UY (1) | UY31604A1 (es) |
| WO (1) | WO2009093747A1 (es) |
| ZA (1) | ZA201005340B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI370820B (en) * | 2005-04-27 | 2012-08-21 | Takeda Pharmaceutical | Fused heterocyclic compounds |
| SG173639A1 (en) * | 2009-02-11 | 2011-09-29 | Sunovion Pharmaceuticals Inc | Histamine h3 inverse agonists and antagonists and methods of use thereof |
| JP2013504581A (ja) * | 2009-09-11 | 2013-02-07 | スノヴィオン ファーマシューティカルズ インコーポレイテッド | ヒスタミンｈ３インバースアゴニストおよびアンタゴニストとその使用方法 |
| CN103857657B (zh) | 2011-08-18 | 2016-04-20 | 日本新药株式会社 | 杂环衍生物及医药 |
| DK2825542T3 (en) | 2012-03-16 | 2017-01-09 | Vitae Pharmaceuticals Inc | LIVER-X-receptor modulators |
| SI2825541T1 (sl) | 2012-03-16 | 2016-10-28 | Vitae Pharmaceuticals, Inc. | Modulatorji jetrnega receptorja X |
| WO2014165816A1 (en) | 2013-04-05 | 2014-10-09 | North Carolina Central University | Compounds useful for the treatment of metabolic disorders and synthesis of the same |
| CN103435618B (zh) * | 2013-08-22 | 2016-03-23 | 中国药科大学 | 一种合成稠杂环化合物的方法 |
| US9771372B2 (en) | 2014-05-23 | 2017-09-26 | Active Biotech Ab | Compounds useful as S100-inhibitors |
| CN105859630B (zh) * | 2015-01-22 | 2019-01-18 | 北京大学 | 一种咪唑酮衍生物的合成方法及应用 |
| US20180269407A1 (en) | 2015-10-01 | 2018-09-20 | Idemitsu Kosan Co., Ltd. | Benzimidazolo[1,2-a]benzimidazole carrying triazine groups for organic light emitting diodes |
| EP3150604B1 (en) | 2015-10-01 | 2021-07-14 | Idemitsu Kosan Co., Ltd. | Benzimidazolo[1,2-a]benzimidazole carrying benzimidazolo[1,2-a]benzimidazolylyl groups, carbazolyl groups, benzofurane groups or benzothiophene groups for organic light emitting diodes |
| WO2018220513A1 (en) * | 2017-05-31 | 2018-12-06 | Alembic Pharmaceuticals Limited | An improved process for preparation of obeticholic acid |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS516993A (en) | 1974-07-05 | 1976-01-20 | Dainippon Pharmaceutical Co | Adeninjudotaino seiho |
| CA2432148C (en) | 2000-12-28 | 2011-01-18 | Ono Pharmaceutical Co., Ltd. | Tri-heterocyclic compounds and a pharmaceutical comprising them as an active ingredient |
| GB0308208D0 (en) * | 2003-04-09 | 2003-05-14 | Glaxo Group Ltd | Chemical compounds |
| WO2004113300A1 (ja) | 2003-06-23 | 2004-12-29 | Ono Pharmaceutical Co., Ltd. | 新規三環性複素環化合物 |
| EP1732541A4 (en) | 2004-04-07 | 2008-03-05 | Takeda Pharmaceutical | CYCLIC COMPOUNDS |
| TWI370820B (en) | 2005-04-27 | 2012-08-21 | Takeda Pharmaceutical | Fused heterocyclic compounds |
| JP2010507664A (ja) | 2006-10-25 | 2010-03-11 | 武田薬品工業株式会社 | ベンズイミダゾール化合物 |
| WO2008082003A1 (en) | 2006-12-29 | 2008-07-10 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compounds having crf antagonistic activity |
| SI2252581T1 (sl) | 2008-01-22 | 2012-09-28 | Lilly Co Eli | Antagonist kappa selektivnega opioidnega receptorja |
| WO2009092566A1 (en) | 2008-01-22 | 2009-07-30 | Boehringer Ingelheim International Gmbh | Substituted amino-benzimidazoles, medicaments comprising said compound, their use and their method of manufacture |
| FR2926556B1 (fr) * | 2008-01-22 | 2010-02-19 | Sanofi Aventis | Derives de carboxamides n-azabicycliques, leur preparation et leur application en therapeutique |
| FR2926554B1 (fr) * | 2008-01-22 | 2010-03-12 | Sanofi Aventis | Derives de carboxamides azabicycliques, leur preparation et leur application en therapeutique |
-
2009
- 2009-01-21 KR KR1020107018307A patent/KR20100130596A/ko not_active Withdrawn
- 2009-01-21 EA EA201070876A patent/EA201070876A1/ru unknown
- 2009-01-21 AU AU2009206936A patent/AU2009206936A1/en not_active Abandoned
- 2009-01-21 SG SG2013029723A patent/SG189803A1/en unknown
- 2009-01-21 PE PE2009000069A patent/PE20091439A1/es not_active Application Discontinuation
- 2009-01-21 UY UY031604A patent/UY31604A1/es not_active Application Discontinuation
- 2009-01-21 NZ NZ587215A patent/NZ587215A/xx not_active IP Right Cessation
- 2009-01-21 CN CN2009801105455A patent/CN101981031A/zh active Pending
- 2009-01-21 TW TW098102200A patent/TW200936591A/zh unknown
- 2009-01-21 BR BRPI0907230A patent/BRPI0907230A2/pt not_active IP Right Cessation
- 2009-01-21 US US12/863,851 patent/US8901141B2/en not_active Expired - Fee Related
- 2009-01-21 CL CL2009000116A patent/CL2009000116A1/es unknown
- 2009-01-21 US US12/357,158 patent/US8785460B2/en not_active Expired - Fee Related
- 2009-01-21 EP EP09704168.5A patent/EP2240485B1/en active Active
- 2009-01-21 MX MX2010008039A patent/MX2010008039A/es not_active Application Discontinuation
- 2009-01-21 AR ARP090100180A patent/AR070218A1/es not_active Application Discontinuation
- 2009-01-21 WO PCT/JP2009/051299 patent/WO2009093747A1/en not_active Ceased
- 2009-01-21 CA CA2712347A patent/CA2712347A1/en not_active Abandoned
- 2009-01-21 JP JP2010528624A patent/JP5431341B2/ja not_active Expired - Fee Related
- 2009-01-21 GE GEAP200911925A patent/GEP20125637B/en unknown
-
2010
- 2010-07-18 IL IL207074A patent/IL207074A0/en unknown
- 2010-07-21 DO DO2010000226A patent/DOP2010000226A/es unknown
- 2010-07-27 ZA ZA2010/05340A patent/ZA201005340B/en unknown
- 2010-08-13 MA MA33084A patent/MA32438B1/fr unknown
- 2010-08-18 CR CR11636A patent/CR11636A/es not_active Application Discontinuation
- 2010-08-20 EC EC2010010414A patent/ECSP10010414A/es unknown
- 2010-08-20 CO CO10102942A patent/CO6230982A2/es active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| EP2240485B1 (en) | 2014-10-15 |
| US20090186879A1 (en) | 2009-07-23 |
| IL207074A0 (en) | 2010-12-30 |
| JP5431341B2 (ja) | 2014-03-05 |
| ZA201005340B (en) | 2011-10-26 |
| JP2011509923A (ja) | 2011-03-31 |
| TW200936591A (en) | 2009-09-01 |
| MA32438B1 (fr) | 2011-07-03 |
| SG189803A1 (en) | 2013-05-31 |
| CL2009000116A1 (es) | 2010-08-27 |
| GEP20125637B (en) | 2012-09-10 |
| CN101981031A (zh) | 2011-02-23 |
| EA201070876A1 (ru) | 2011-04-29 |
| US20100298287A1 (en) | 2010-11-25 |
| NZ587215A (en) | 2012-08-31 |
| DOP2010000226A (es) | 2010-10-15 |
| CA2712347A1 (en) | 2009-07-30 |
| CO6230982A2 (es) | 2010-12-20 |
| PE20091439A1 (es) | 2009-10-19 |
| KR20100130596A (ko) | 2010-12-13 |
| UY31604A1 (es) | 2009-08-31 |
| ECSP10010414A (es) | 2010-09-30 |
| CR11636A (es) | 2010-11-04 |
| EP2240485A1 (en) | 2010-10-20 |
| MX2010008039A (es) | 2010-08-10 |
| WO2009093747A1 (en) | 2009-07-30 |
| US8901141B2 (en) | 2014-12-02 |
| BRPI0907230A2 (pt) | 2019-09-24 |
| AU2009206936A1 (en) | 2009-07-30 |
| US8785460B2 (en) | 2014-07-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR070218A1 (es) | COMPUESTOS TRICíCLICOS, SUS PROFÁRMACOS, UNA COMPOSICIoN FARMACÉUTICA QUE LOS COMPRENDE Y SU USO EN LA PRODUCCIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR EL RECEPTOR CRF. | |
| UY31127A1 (es) | Ligandos de oxiadazol del receptor metabotropico para el glutamato y su utilizacion como potenciadores - 841 | |
| UY32296A (es) | Nuevos compuestos | |
| ECSP15012804A (es) | Alcoxipirazoles como activadores de guanilato ciclasa soluble | |
| UY31069A1 (es) | Nuevos derivados de imidazoquinola, composiciones conteniendolos, proceso de preparacion y aplicaciones | |
| GT201400031A (es) | Derivados de 2-amino-4-(piridin-2-il)-5,6-dihidro-4h-1,3-oxazina y su uso como inhibidores de bace-1 y/o bace-2 | |
| ECSP11011470A (es) | Nuevos derivados de pirimidina y sus usos en el tratamiento del cáncer y otras enfermedades | |
| ECSP109856A (es) | Derivados de oxadiazol y su uso como potenciadores de los receptores metabotrópicos de glutamato - 842 | |
| CO6382155A2 (es) | Agonistas del receptor gpr120 de arilo y usos de los mismos | |
| UY32611A (es) | Compuestos de 1-cianoetilheterociclilcarboxamida sustituidos 750 | |
| NI201002091A (es) | Derivados de isoxazol y su uso como potenciadores de los receptores metabotrópicos de glutamato. | |
| UY33078A (es) | Derivados de imidazoquinolina | |
| PH12014500813A1 (en) | Novel [1,2,3] triazolo [4,5-d] pyrimidine derivatives as agonists of the cannabinoid receptor | |
| ECSP14013215A (es) | Compuestos novedosos | |
| UY33458A (es) | Derivados de metoxifenilo heterocíclicamente sustituidos con un grupo oxo, procedimientos para su preparación y uso de los mismos como medicamentos | |
| UY32574A (es) | Antagonistas del receptor cxcr3 | |
| UY33075A (es) | Derivados de ciclohexano y usos de los mismos | |
| ECSP099751A (es) | Derivados de 9-(pirazol-3-il)-9h-purin-2-amina y 3-(pirazol-3-il)-3h-imidazo[4,5-b]piridin-5-amina y su uso para el tratamiento del cáncer | |
| DOP2009000200A (es) | Derivados de 2-amino-5,7-dihidro-6h-pirrolo[3,4-d] pimiridina como inhibidores hsp-90 para tratar el cancer | |
| AR078278A1 (es) | Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro. | |
| BR112012001817B8 (pt) | furazanobenzimidazóis, seu uso, processo de produção e composição farmacêutica | |
| CR10356A (es) | Derivados de 4-benzilphthalazinona 2-sustituidos como antagonistas de histamina h1 y h3 | |
| UY29988A1 (es) | Compuestos de oxazolidinona y su uso como potenciadores del receptor metabotrópico de glutamato | |
| UY32055A (es) | Derivados sustituidos de la 5-Halo-N2-[sustituido](1-metil-1H-imidazol-4-il)pirimidin-2,-diamina y sus sales farmacéuticamente aceptables, procesos de preparación, composiciones y aplicaciones. | |
| ECSP099425A (es) | Derivados de amina y su uso en enfermedades mediadas por el adrenorecetor beta 2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |